ArticleLeukemia2017

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

C Schütz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.